There may be drugs at the industry's fingertips, already approved, that could be of value in treating patients with neurodegenerative disease if repurposed and brought to regulatory approval for expanded indications, but these may be stalled due to rundown patents and a lack of financial incentive in the market, according the a study published June 24 in the Annals of Clinical and Translational Neurology.

The American Academy of Neurology (AAN) and the American Brain Foundation announced yesterday that they have named former NFL champion Ben Utecht an official, nationwide spokesperson for the AAN. Utecht will now be charged with advocating awareness of sports concussions and their dangers.

The 19th world congress on heart disease organized by the International Academy of Cardiology will be covering the cutting edge of cardiovascular research, including molecular and cellular cardiology, from July 25-28 at the Hyatt Regency Boston.

Lantheus Holdings, parent company to Lantheus Medical Imaging, a global leader in developing, manufacturing, selling and distributing innovative diagnostic imaging agents, announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed initial public offering of its common stock. Lantheus Holdings intends to apply to list its common stock on the NASDAQ Global under the ticker symbol "LNTH." The number of shares to be offered and the price range of the proposed offering have not yet been determined. Lantheus Holdings expects to use the net proceeds of the offering to repay indebtedness of LMI and for working capital and general corporate purposes.

An investigational amyloid antibody treatment called solanezumab is being evaluated by Northwestern University School of Medicine and Rush University Medical Center in Chicago for its efficacy in slowing memory loss caused by Alzheimer's disease.

Using a multiparametric approach, PET/MR imaging with F-18 FDG, dynamic contrast-enhanced MRI, diffusion-weighted imaging and 3-D proton MR spectroscopic imaging is superior for telling apart different kinds of breast tumors, according to a study published online June 24 in Clinical Cancer Research.

ImaginAb announced earlier this month that IBA Molecular will be taking on radiochemistry, manufacturing and distribution of the diagnostic immunoPET agent for prostate cancer, Zr-89 Df-IAB2M, as U.S. clinical trials roll out.

Regenerative medicine is generating growing interest in terms of research and market investment, according to a data analysis announced June 18 by Frost & Sullivan.